Publications

5491 Results

Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib

Authors
V Wang;C Hanson;R Tschumper;C Lesnick;E Braggio;E Paietta;S O'Brien;J Barrientos;J Leis;C Zhang;S Coutre;P Barr;A Cashen;A Mato;A Singh;M Mullane;H Erba;R Stone;M Litzow;M Tallman;T Shanafelt;N Kay
Journal / Conference
Blood, Aug 18;blood.2020010146. doi: 10.1182/blood.2020010146. Online ahead of print.
Year
2021
Research Committee(s)
Leukemia
PMID
PMID34407545
Study Number(s)
CTSU/E1912

Reply to John T. Lafin, Aditya Bagrodia’s Letter to theEditor re: Lucia Nappi, Marisa Thi, Nabil Adra, et al.Integrated Expression of Circulating miR375 andmiR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. Eur Urol 2021;79:16–9

Authors
L Nappi;C Nichols;C Kollmannsberger
Journal / Conference
European Urology, Mar;79(3):e85-e86
Year
2021
Research Committee(s)
Prevention and Epidemiology
PMID
PMID33357996
Study Number(s)
S1823

Clinical trials as a path toward equity [Editorial]

Authors
A Benson;R Carlos
Journal / Conference
Cancer, Oct 15; 127(20):3717-3719
Year
2021
Research Committee(s)
Gastrointestinal
PMID
PMID34374076
Study Number(s)
CTSU/C80405

Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program

Authors
L McLouth;C Nightingale;E Dressler;A Snavely;M Hudson;JM Unger;A Kazak;S Lee;J Edward;R Carlos;C Kamen;H Neuman;K Weaver
Journal / Conference
Cancer Epidemiology, Biomarkers & Prevention, Apr;30(4):669-675
Year
2021
Research Committee(s)
Cancer Care Delivery
PMID
PMID33355237
PMC
PMC8026561

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes

Authors
A Nazha;R Komrokji;M Meggendorfer;X Jia;N Radakovich;J Shreve;C Hilton;Y Nagata;B Hamilton;S Mukherjee;N Al Ali;W Walter;S Hutter;E Padron;D Sallman;T Kuzmanovic;C Kerr;V Adema;D Steensma;A Dezern;G Roboz;G Garcia-Manero;H Erba;C Haferlach;J Maciejewski;T Haferlach;M Sekeres
Journal / Conference
Journal of Clinical Oncology, Aug 18;JCO2002810. doi: 10.1200/JCO.20.02810. Online ahead of print
Year
2021
Research Committee(s)
Leukemia
PMID
PMID34406850
Study Number(s)
S1117

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Authors
Y Wang;S Liu;A Algazi;S Lomeli;Y Wang;M Othus;A Hong;Z Wang;C Randolph;A Jones;M Bosenberg;S Byrum;A Tackett;H Lopez;C Yates;D Solit;A Ribas;M Piva;G Moriceau;R Lo
Journal / Conference
Cancer Cell, Aug 18;S1535-6108(21)00402-5. doi: 10.1016/j.ccell.2021.07.023. Online ahead of print.
Year
2021
Research Committee(s)
Melanoma
PMID
PMID34416167
Study Number(s)
S1320

Classical Hodgkin lymphoma [Review]

Authors
P Brice;E de Kerviler;J Friedberg
Journal / Conference
Lancet, Jan 22;S0140-6736(20)32207-8. doi: 10.1016/S0140-6736(20)32207-8. Online ahead of print
Year
2021
Research Committee(s)
Lymphoma
PMID
PMID33493434
Study Number(s)
S0816

Adherence with protocol medication use and mortality from unrelated causes in a prevention trial

Authors
P Pinsky;P Goodman;H Parnes;L Ford;L Minasian
Journal / Conference
Preventive Medicine Dec;153:106778
Year
2021
Research Committee(s)
Cancer Control
PMID
PMID34450188
Study Number(s)
SWOG-9217

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

Authors
A Partridge;S Niman;M Ruggeri;F Peccatori;H Azim;M Colleoni;C Saura;C Shimizu;A Saetersdal;J Kroep;A Mailliez;E Warner;V Borges;F Amant;A Gombos;A Kataoka;C Rousset-Jablonski;S Borstnar;J Takei;J Lee;J Walshe;M Ruiz Borrego;HCF Moore;C Saunders;F Cardoso;S Susnjar;V Bjelic-Radisic;K Smith;M Piccart;L Korde;A Goldhirsch;R Gelber;O Pagani
Journal / Conference
Breast, Aug 3;59:327-338. doi: 10.1016/j.breast.2021.07.021. Online ahead of print.
Year
2021
Research Committee(s)
Cancer Survivorship
PMID
PMID34390999
PMC
PMC8365381

Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.

Authors
E Fontana;J Meyers;A Sobrero;A Iveson;AF Shields;J Taieb;T Yoshino;I Souglakos;E Smyth;F Lordick;M Moehler;A Harkin;R LaBianca;J Meyerhardt;T Andre;T Yamanaka;I Boykovinas;A Grothey;I Ben-Aharon
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 3517); (ASCO 2021 Annual Meeting), poster discussion
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702